Archives: Corporate

Subscribe to Corporate RSS Feed

The CDA – Five Practical Considerations

The Confidential Disclosure Agreement (“CDA”) is widely used in the Life Sciences Sector, and provides protection for a key asset – a party’s confidential information and trade secrets.  This post does not propose to go through the various possible provisions of a CDA or their negotiation, but instead sets out five practical considerations to take into … Continue Reading

Ten Considerations When Taking a Licence From a University

Taking a licence from a university or other academic institution raises specific considerations in addition to those that would normally apply in a purely commercial setting.  We set out below ten key considerations for any commercial entity taking a licence from a university in the EU. 1. Continuing academic research in the field and publication … Continue Reading

The Association of British Insurers (ABI) Publishes a Review of Capital Raising in the UK Market

On 11 July 2013, the ABI published the findings of its extensive review of processes for initial public offerings (IPOs) and secondary capital raisings in the UK public market.  The ABI Report follows a government-funded independent review by Professor Kay (released July 2012), which examined investment in UK equity market and its impact on the … Continue Reading

The Perils of One-Way Jurisdiction Clauses

Overview A one-way jurisdiction clause (also known as “hybrid”, “asymmetrical” or “unilateral non-exclusive” jurisdiction clauses), requires that one of the parties to a contract must always submit a dispute arising from the contract to a particular country’s courts, whilst allowing the other party the flexibility to commence proceedings in the courts of any country it … Continue Reading

Key Considerations for European M&A in the Life Sciences Sector

Article originally published in PLC Life Sciences Handbook 2012 M&A in the life sciences sector has remained robust, driven by factors such as: „„ The need to replenish shrinking product pipelines. „„ The need to maintain revenues as patents on top-selling products expire. „„ The strategic diversification of business lines. „„ Expansion into emerging markets. … Continue Reading

Pharma Buy

Article originally published in The Lawyer on October 14, 2010 Despite global economic conditions, deal-making by large pharmaceutical companies has remained relatively buoyant, say Daniel Pavin, Grant Castle and Alexandra Pygall. Acquisitions in the pharmaceuticals sector are being driven by factors such as the need to replenish shrinking product pipelines, the need to maintain revenues … Continue Reading

Pharma and Biotech In-licensing and Collaboration Agreements: a Deal Lawyer’s Guide to EU Anti-trust pitfalls

Article originally published in the Cross-border Life Sciences Handbook 2006/07 Pharmaceutical and biotech companies are turning with increasing frequency to in-licensing and collaboration agreements – pharmaceutical companies to put new products in their pipelines and biotech companies to access the resources needed for final-stage development, clinical trials, manufacturing, and distribution. One result of the increasing importance … Continue Reading